ARTICLE | Clinical News
CB-315: Phase III started
July 16, 2012 7:00 AM UTC
Cubist began the first of a pair of identical, double-blind, international Phase III trials to compare 250 mg twice-daily CB-315 vs. 125 mg once-daily vancomycin for 10 days in 608 patients each. ...